Table 1.
Patient, Tumor and Treatment Characteristics
| Characteristic | All Patients (n=37) |
|---|---|
| Age at oligorecurrence before mdSBRT, years | |
| Mean (± SD) | 67.6 (7.6) |
| Median (IQR) | 69 (63–73) |
| Time between PCa diagnosis and mdSBRT, months | |
| Mean (± SD) | 63.2 (43.7) |
| Median (IQR) | 54 (31–85) |
| PSA at PCa diagnosis, ng/ml | |
| Mean (± SD) | 21.9 (44.5) |
| Median (IQR) | 6.75 (4.7–16.2) |
| Treatment at PCa diagnosis | |
| RT | 5 (13.5) |
| RP | 27 (73.0) |
| RP + Adjuvant RT | 5 (13.5) |
| Primary Tumor (T) at PCa diagnosis | |
| p/c T1 | 3 (8.1) |
| p/c T2 | 15 (40.5) |
| p/c T3a | 6 (16.2) |
| p/c T3b | 13 (35.1) |
| Lymph Nodes (N) at PCa diagnosis | |
| p/c N0 | 32 (86.5) |
| p N1 | 5 (13.5) |
| Gleason score at PCa diagnosis | |
| ≤ 6 | 1 (2.7) |
| 7 | |
| ≥ 8 | |
| PSA at oligorecurrence, ng/ml | |
| Mean (± SD) | 6.9 (16.3) |
| Median (IQR) | 4.4 (1.3–6.2) |
| PSA doubling time at oligorecurrence, months | |
| Mean (± SD) | 4.6 (4.0) |
| Median (IQR) | 3 (1.9–5.9) |
| PSA velocity at oligorecurrence, ng/ml/yr | |
| Mean (± SD) | 13.0 (35.1) |
| Median (IQR) | 4.1 (1.3–10.4) |
| Castrate-resistant at oligorecurrence | |
| Yes | 12 (32.4) |
| No | 25 (67.6) |
| Number of mdSBRT treated site(s) | |
| 1 | 31 (83.8) |
| 2 | 4 (10.8) |
| 3 | 2 (5.4) |
| Location of mdSBRT treated site(s) | |
| Non-spinal osseous | 25 (67.6) |
| Spinal | 5 (13.5) |
| Lymph node | 1 (2.7) |
| Spinal + Non-spinal osseous | 6 (16.2) |
| Dose and Fractionation of mdSBRT | |
| 30 Gy in 3 Fractions | 11 (29.7) |
| 24 Gy in 1 Fraction | 2 (5.4) |
| 18 Gy in 1 Fraction | 20 (54.1) |
| 16 Gy in 1 Fraction | 4 (10.8) |
| Androgen Deprivation Therapy | |
| Concurrent with and adjuvant to mdSBRT | 19 (51.4) |
| Delayed until additional progression | 18 (48.6) |
Abbreviations: mdSBRT, metastasis-directed Stereotactic Body Radiation Therapy; PSA, prostate specific antigen; SD, Standard Deviation; IQR, Interquartile Range.